06-01-2017
Lemau Studio / Shutterstock.com
Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent (alirocumab) after Amgen obtained an injunction against the companies.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Amgen, Sanofi, Regeneron Pharmaceuticals, patent, patent infringement, evolocumab, Repatha, Praluent, injunction
AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling
17-10-2017
Federal Circuit vacates Amgen injunction in Sanofi suit
06-10-2017
Sanofi and Regeneron’s appeal to suspend Amgen injunction denied
12-01-2017
Sanofi and Regeneron to appeal against Praluent injunction
09-01-2017
Amgen secures patent win in Repatha case
04-01-2017
